Innoviva Profit Margin 2010-2024 | INVA

Current and historical gross margin, operating margin and net profit margin for Innoviva (INVA) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Innoviva net profit margin as of September 30, 2024 is 18.31%.
Innoviva Annual Profit Margins
Innoviva Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.161B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $742.697B 76.93
Novo Nordisk (NVO) Denmark $487.391B 35.15
Johnson & Johnson (JNJ) United States $352.091B 14.28
AbbVie (ABBV) United States $306.051B 16.11
Merck (MRK) United States $256.126B 17.02
AstraZeneca (AZN) United Kingdom $207.555B 17.66
Novartis AG (NVS) Switzerland $201.518B 13.40
Pfizer (PFE) United States $143.772B 9.83
Sanofi (SNY) $119.253B 10.80